First Wave BioPharma engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Co. is focused on developing its drug product candidate, MS1819, a yeast derived recombinant lipase for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. Co.'s b-lactamase program focuses on products with an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea by resistant bacterial strains induced by parenteral administration of several antibiotic classes. Co.'s compounds in pre-clinical development include: AZX1101 and AZX1103. The FWBI YTD return is shown above.
The YTD Return on the FWBI YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether FWBI YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the FWBI YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|